CompletedNot Applicable

The Impact of Mitotane Therapy on Serum Free Proteins in Patients With Adrenocortical Carcinoma

United Kingdom35 participantsStarted 2022-04-11

Plain-language summary

This work will evaluate the effects of mitotane treatment on serum protein concentrations in patients treated for ACC with mitotane therapy and compare them to patients with an adrenal neoplasm and pregnant cohort. All of the individuals were treated at King's Hospital between April 2019 and June 2020. Proteins which will be evaluated during this study, include CBG and TBG.

Who can participate

Age range19 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: An individual being investigated for a malignant neoplasm treated with mitotane or matched number of patients with adrenal neoplasm not treated with mitotane under the Endocrinology team or a matched cohort of pregnant women. Patients included in the analysis were seen in the period between April of 2019 and June 2020 at King's College Hospital NHS Foundation Trust. \- Exclusion Criteria: * Patients not investigated for a malignant neoplasm/ adrenal neoplasm under the Endocrinology team or were a matched cohort of pregnant women at King's College Hospital NHS Foundation Trust during the period Someone under the age of 18

What they're measuring

Examine the effect of mitotane therapy on serum thyroid and cortisol binding proteins in patients with ACC

Timeframe: April 2019-June 2020

Trial details

NCT IDNCT05344027

SponsorKing's College Hospital NHS Trust

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-01-30

View on ClinicalTrials.gov More Adrenocortical Carcinoma trials